Subtracting First Principal Component May Improve 4R Tau Detectability on [ 18 F]Flortaucipir Tau PET
Authors:
- 22 January 2026
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 67 (4) , 636-643
Abstract
[18F]flortaucipir PET imaging has shown relatively low sensitivity for detecting four-repeat (4R) tau, which limits its utility in 4R tauopathies such as progressive supranuclear palsy (PSP). Previous studies have suggested that the first component of principal-component analysis includes non-disease-related uptake in non-Alzheimer tauopathies. In this study, we tested the hypothesis that subtracting this component could increase sensitivity to 4R tau using a large PSP cohort. Methods: Prospectively recruited patients with PSP (n = 141; 80 Richardson syndrome, 44 PSP-subcortical, and 17 PSP-cortical variants) and controls (n = 102) underwent [18F]flortaucipir PET. The first principal component (PC1) was extracted from the SUV ratio (SUVR) images of 62 controls and then subtracted from the remaining controls (n = 40) and all PSP patients. We compared the diagnostic performance before and after PC1 subtraction by evaluating SUVR differences between PSP and controls, as well as across PSP clinical variants, and by calculating correlation coefficients between SUVR and the severity of tau pathology. Results: Area under the receiver operating characteristic curves differentiating PSP and controls were improved by PC1 subtraction in the frontal white matter (0.54 to 0.67; P = 0.002) and subcortical (0.69 to 0.87; P < 0.001) regions. In the frontal regions, no differences were observed across PSP clinical variants before PC1 subtraction, whereas the PSP-cortical variant showed an SUVR higher than that of the PSP Richardson syndrome and PSP-subcortical variants after PC1 subtraction (adjusted P < 0.05). A correlation with the severity of tau pathology was observed only in the red nucleus before PC1 subtraction, whereas correlations were observed in the precentral, superior frontal gyrus, and red nucleus after PC1 subtraction (adjusted P < 0.05). Conclusion: Our approach enhanced the diagnostic performance of [18F]flortaucipir PET in PSP and increased sensitivity to 4R tau, suggesting that subtracting the first principal component improves the detectability of subtle 4R tau uptake and the potential utility of [18F]flortaucipir PET imaging for non-Alzheimer tauopathies.Keywords
This publication has 21 references indexed in Scilit:
- Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsyNeuroImage, 2024
- Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysisJournal of Neurology, 2023
- Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic ChangesJAMA Neurology, 2020
- Distribution patterns of tau pathology in progressive supranuclear palsyActa Neuropathologica, 2020
- Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography featuresMovement Disorders, 2019
- MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear PalsyMovement Disorders, 2018
- A re‐examination of Montreal Cognitive Assessment (MoCA) cutoff scoresInternational Journal of Geriatric Psychiatry, 2017
- Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Movement Disorders, 2017
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaMovement Disorders, 2017
- Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degenerationJournal of Neurology, 1999